Screening for Down's Syndrome: The First Two Years Experience in Bristol

Abstract

Objectives

– To evaluate the effectiveness of a programme for antenatal screening for Down's syndrome using a fetoprotein and total human chorionic gonadotrophin as maternal serum markers.

Setting

–A district general hospital providing a screening service to a local purchasing authority and (under contract) to another purchasing authority in the same region.

Methods

– Patients were counselled and screened between 15 and 20 weeks gestation and Down's risk estimates calculated using the maternal serum marker results as modifiers of the age related risk. Outcome was determined in collaboration with the Regional Cytogenetics Unit.

Outcome Measures

– Detection rate for Down's syndrome, false positive rate, uptake of screening, and uptake of amniocentesis.

Results–

In two years 22 816 women were screened (approximately 84% of population); 32 Down's pregnancies were identified, 19 (59.4%) had a reported risk of ≥1:250 and 20 (62.5%) a reported risk of ≥1:300. Of those screened before 17 weeks, 16/20 (80%) had a reported risk of ≥1: 300 compared with 4/12 (33%) of those screened later (P = 0.008); 4.64% of patients screened had reported risks ≥1: 250 and 5.87% reported risks of ≥ 1:300. Amniocentesis uptake was 70% in patients with reported risks of ≥ 1:300.

Conclusions

–Overall the screening programme was effective but screening before 17 weeks was very much more effective than screening later.

Keywords

Down's screening α fetoprotein total chorionic gonadotrophin

References

Report of the RCOG working party on biochemical markers and the detection of Down's syndrome. London: RCOG Press, 1993.

Cuckle

Multimarker screening for Down's syndrome. Diplomate 1994;2:104–9.

Reynolds

Penney

. The mathematical basis of multivariate risk screening: With special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1990;27:452–8.

Wald

Cuckle

Densen

Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883–7.

Cuckle

Wald

Thompson

. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387–402.

Altman

. Practical statistics for medical research. London: Chapman and Hall, 1991:234.

Spencer

Coombes

Mallard

Ward

Milford A.

Free beta human choriogonadotropin in Down's syndrome screening; a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 1992;29:506–18.

Fleming

Goldie

. Risk of Down's syndrome and amniocentesis rate. BMJ 1992;304:252.

Hook

. Chromosome abnormalities and spontaneous fetal death following amniocentesis: Further data and associations with maternal age. Ann J Hum Genet 1983;35:110–6.